Sprint Bioscience Q4: Confident expansion - Redeye

Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.3m (SEK 14.8m in Q3), mostly related to the Day One Biopharmaceuticals partner and the VADA project. The cash balance was SEK 25.1m in Q4 (SEK 31.7m in Q3 and 36m in Q2 2024). Sprint Bioscience continues to market and engage in conversations with potential partners for VP34, TREX1 (DISA), NIMA and MASH programs. During the quarter, Sprint Bioscience is also evaluating the PETRA01 program.

Länk till analysen i sin helhet: https://www.redeye.se/research/1076008/sprint-bioscience-q4-confident-expansion?utm_source=finwire&utm_medium=RSS